Diabetic Foot Files

Dr. G discusses pyomyositis — a deep skeletal muscle infection that can occur in people with diabetes, how it differs from cellulitis, its stages, common causes, typical pathogens, diagnostic steps including MRI and labs, and the importance of source control, imaging, and vascular assessment.

Key takeaways: the visible ulcer may be only the surface of a deeper infection, early recognition and imaging are critical, and management often requires both antibiotics and surgical drainage plus attention to offloading and vascular status.

Dr. G explains pyroptosis — an inflammatory form of programmed cell death driven by inflammasomes, caspase‑1, and gasdermin D — and how its pore‑forming, cytokine‑releasing shutdown can amplify inflammation.

The episode explores how pyroptosis affects keratinocytes, fibroblasts, and macrophages in diabetic foot ulcers, potentially preventing healing by keeping danger signaling active, and why balancing this response matters for recovery.

This episode explains what NPO (nil per os) means, why clinicians use it to reduce aspiration risk during anesthesia or procedures, and why it’s more complex for people with diabetes.

Key points include glucose monitoring every 2–4 hours, tailored insulin and medication plans, risks from gastroparesis, and the importance of asking the care team specific questions about allowed intake and medication adjustments.

Dr. G introduces Peculiar Podiatry with a deep dive into the "purple toe"—a visual clue that can mean anything from a simple bruise to dangerous arterial or venous problems, infection, or neuropathy, especially in people with diabetes.

This episode explains how to evaluate timing, pain, pulses, position changes, and when urgent vascular or emergency care is needed.

Dr. G explores how capsaicin, the active compound in chili peppers, can reduce burning neuropathic pain by overactivating and desensitizing pain-sensing nerves.

The episode explains that capsaicin is not a cure for diabetic neuropathy or a treatment for ulcers, notes differences between low‑dose creams and the 8% prescription patch, and highlights safety precautions (apply only to intact skin, avoid eyes/mucous membranes, and have trained clinicians administer high‑dose patches).